CytomX Therapeutics, Inc. (CTMX)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-07) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-16) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-12) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-03-06) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-07) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-08) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-08) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-03-11) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-07) · 99.1 | ||
| 10-K/A | FY-2021 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Balance Sheets | ||
| Balance Sheets (P) | — |
|
| Condensed Statements of Operations and Comprehensive Income | — |
|
| Statements of Operations and Comprehensive Income (loss) | ||
| Statements of Operations and Comprehensive Loss | ||
| Condensed Statements of Stockholders' Equity (deficit) | — |
|
| Statements of Cash Flows | ||
| Statements of Stockholders' Deficit | ||
| Notes | ||
| Accrued Liabilities | ||
| Basis of Presentation and Summary of Significant Accounting Policies | ||
| Collaboration and License Agreements | ||
| Commitments and Contingencies | ||
| Common Stock | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Defined Contribution Plan | — |
|
| Description of The Business | ||
| Fair Value Measurements and Investments | ||
| Income Taxes | ||
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Intangible Asset | — |
|
| Leases | ||
| License Agreement | ||
| Net Income (loss) Per Share | ||
| Net Income Per Share | — |
|
| Net Loss Per Share | ||
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Restructuring | ||
| Segment | — |
|
| Segment Disclosures | ||
| Stock-based Compensation | ||
| Subsequent Event | ||